Pharsight

Onzetra Xsail patents expiration

ONZETRA XSAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices
Jul, 2023

(8 months ago)

US8327844 CURRAX Nasal delivery method
Oct, 2023

(5 months ago)

US9119932 CURRAX Nasal delivery device
Apr, 2024

(25 days from now)

US7975690 CURRAX Nasal devices
Aug, 2025

(1 year, 4 months from now)

US8590530 CURRAX Nasal delivery devices
Sep, 2025

(1 year, 5 months from now)

US9108015 CURRAX Nasal delivery devices
Sep, 2025

(1 year, 5 months from now)

US11571531 CURRAX Powder delivery devices
Feb, 2026

(1 year, 10 months from now)

US10124132 CURRAX Nasal delivery
Mar, 2027

(2 years from now)

US10398859 CURRAX Nasal delivery devices
Dec, 2027

(3 years from now)

US8875704 CURRAX Nasal administration
Apr, 2028

(4 years from now)

US10722667 CURRAX Nasal administration
Dec, 2028

(4 years from now)

US10076615 CURRAX Nasal delivery
Jul, 2029

(5 years from now)

US8550073 CURRAX Nasal delivery
Oct, 2029

(5 years from now)

US8899229 CURRAX Powder delivery devices
Aug, 2030

(6 years from now)

US9649456 CURRAX Nasal administration
Oct, 2030

(6 years from now)

US8978647 CURRAX Nasal delivery
Dec, 2030

(6 years from now)

US10478574 CURRAX Nasal administration
Nov, 2033

(9 years from now)

US10076614 CURRAX Nasal delivery devices
Oct, 2034

(10 years from now)

Onzetra Xsail is owned by Currax.

Onzetra Xsail contains Sumatriptan Succinate.

Onzetra Xsail has a total of 18 drug patents out of which 2 drug patents have expired.

Expired drug patents of Onzetra Xsail are:

  • US8047202
  • US8327844

Onzetra Xsail was authorised for market use on 27 January, 2016.

Onzetra Xsail is available in powder;nasal dosage forms.

Onzetra Xsail can be used as acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity, method of delivering sumatriptan to a nasal cavity, method of drug delivery via the nasal cavity, treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity, acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device.

The generics of Onzetra Xsail are possible to be released after 20 October, 2034.

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; T...

Dosage: POWDER;NASAL

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents